Close Menu

NEW YORK (GenomeWeb) – Canaccord and William Blair have upgraded their ratings on Quidel’s shares to Buy and Outperform, respectively, based on its acquisition of Alere's Triage B-type natriuretic peptide assay and cardiovascular and toxicology diagnostic assets, announced yesterday.

Quidel agreed to pay $400 million for the assets and $40 million in contingent consideration. It expects the deal to close by Sept. 20.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.